Cargando…

Association of Pulmonary Sepsis and Immune Checkpoint Inhibitors: A Pharmacovigilance Study

SIMPLE SUMMARY: This study investigates the association of pulmonary sepsis with immune checkpoint inhibitors by conducting an analysis using data from the Food and Drug Administration pharmacovigilance database. Compared to chemotherapy or targeted therapy, a robust signal emerged for nivolumab and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xia, Shuang, Gong, Hui, Zhao, Yichang, Guo, Lin, Wang, Yikun, Zhang, Bikui, Sarangdhar, Mayur, Noguchi, Yoshihiro, Yan, Miao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818197/ https://www.ncbi.nlm.nih.gov/pubmed/36612235 http://dx.doi.org/10.3390/cancers15010240

Ejemplares similares

Do antibody–drug conjugates increase the risk of sepsis in cancer patients? A pharmacovigilance study
por: Xia, Shuang, et al.
Publicado: (2022)

Pneumocystis jirovecii pneumonia associated with immune checkpoint inhibitors: A systematic literature review of published case reports and disproportionality analysis based on the FAERS database
por: Xia, Shuang, et al.
Publicado: (2023)

Pharmacovigilance Evaluation of the Association Between DPP-4 Inhibitors and Heart Failure: Stimulated Reporting and Moderation by Drug Interactions
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Pharmacovigilance assessment of the association between Fournier’s gangrene and other severe genital adverse events with SGLT-2 inhibitors
por: Fadini, Gian Paolo, et al.
Publicado: (2019)

Immune checkpoint inhibitor-induced aplastic anaemia: Case series and large-scale pharmacovigilance analysis
por: Guo, Qian, et al.
Publicado: (2023)

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
por: Johnson, Douglas B., et al.
Publicado: (2019)

Metabolic and Nutritional Disorders Following the Administration of Immune Checkpoint Inhibitors: A Pharmacovigilance Study
por: Zhai, Yinghong, et al.
Publicado: (2022)

Hepatotoxicity in immune checkpoint inhibitors: A pharmacovigilance study from 2014–2021
por: Xu, Ze, et al.
Publicado: (2023)

Cardiotoxicity Induced by Immune Checkpoint Inhibitors: A Pharmacovigilance Study From 2014 to 2019 Based on FAERS
por: Chen, Chenxin, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database
por: Ruggiero, Rosanna, et al.
Publicado: (2020)

Editorial: Pharmacovigilance and drug repositioning research using pharmacoepidemiology
por: Noguchi, Yoshihiro, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor-Related Cytokine Release Syndrome: Analysis of WHO Global Pharmacovigilance Database
por: Ceschi, Alessandro, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor–Associated Tumor Lysis Syndrome: A Real-World Pharmacovigilance Study
por: Wang, Li, et al.
Publicado: (2021)

Pancreatic Adverse Events Associated With Immune Checkpoint Inhibitors: A Large-Scale Pharmacovigilance Analysis
por: Zhang, Yue, et al.
Publicado: (2022)

Immune Checkpoint Inhibitor-Related Cytopenias: About 68 Cases from the French Pharmacovigilance Database
por: Martin, Mickaël, et al.
Publicado: (2022)

Musculoskeletal adverse events induced by immune checkpoint inhibitors: a large-scale pharmacovigilance study
por: Liu, Hao, et al.
Publicado: (2023)

Hemophagocytic Lymphohistiocytosis Associated with Immunological Checkpoint Inhibitors: A Pharmacovigilance Study
por: Diaz, Laurine, et al.
Publicado: (2023)

Clinical pharmacy undergraduate education in China: a comparative analysis based on ten universities’ training programs
por: Li, Jiakai, et al.
Publicado: (2023)

Renal toxicities in immune checkpoint inhibitors with or without chemotherapy: An observational, retrospective, pharmacovigilance study leveraging US FARES database
por: Hu, Fangyuan, et al.
Publicado: (2021)

Graft Versus Host Disease Associated with Immune Checkpoint Inhibitors: A Pharmacovigilance Study and Systematic Literature Review
por: Nguyen, Lee S., et al.
Publicado: (2021)

Pericardial Toxicities Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database
por: Ma, Zhuo, et al.
Publicado: (2021)

Bone fracture as a novel immune‐related adverse event with immune checkpoint inhibitors: Case series and large‐scale pharmacovigilance analysis
por: Filippini, Daria Maria, et al.
Publicado: (2021)

Pulmonary Complications Secondary to Immune Checkpoint Inhibitors
por: Albitar, Hasan Ahmad Hasan, et al.
Publicado: (2020)

Immune checkpoint inhibitors
por: Hui, Enfu
Publicado: (2019)

Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
por: Zhou, Chaozheng, et al.
Publicado: (2023)

Risk factors of immune checkpoint inhibitor-associated acute kidney injury: evidence from clinical studies and FDA pharmacovigilance database
por: Chen, Pengwei, et al.
Publicado: (2023)

Targeting Immune Cell Checkpoints during Sepsis
por: Patil, Naeem K., et al.
Publicado: (2017)

Subset Analysis for Screening Drug–Drug Interaction Signal Using Pharmacovigilance Database
por: Noguchi, Yoshihiro, et al.
Publicado: (2020)

Management of pulmonary toxicity associated with immune checkpoint inhibitors
por: Delaunay, Myriam, et al.
Publicado: (2019)

Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance
por: Raschi, Emanuel, et al.
Publicado: (2020)

Urinary incontinence as a possible signal of neuromuscular toxicity during immune checkpoint inhibitor treatment: Case report and retrospective pharmacovigilance study
por: Hu, Yizhang, et al.
Publicado: (2022)

Cardiovascular toxicity profiles of immune checkpoint inhibitors with or without angiogenesis inhibitors: a real-world pharmacovigilance analysis based on the FAERS database from 2014 to 2022
por: Wang, Yanfeng, et al.
Publicado: (2023)

Allograft rejection following immune checkpoint inhibitors in solid organ transplant recipients: A safety analysis from a literature review and a pharmacovigilance system
por: Cui, Xiangli, et al.
Publicado: (2022)

Using Systems Biology-based Analysis Approaches to Identify Mechanistically Significant Adverse Drug Reactions: Pulmonary Complications from Combined Use of Anti-TNFα Agents and Corticosteroids
por: Sarangdhar, Mayur, et al.
Publicado: (2013)

Immune checkpoint inhibitors break whose heart? Perspectives from cardio-immuno-oncology
por: He, Yingying, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: Focus on Nivolumab
por: Bukamur, Hazim, et al.
Publicado: (2020)

Stevens-Johnson syndrome/toxic epidermal necrolysis in patients treated with immune checkpoint inhibitors: A safety analysis of clinical trials and FDA pharmacovigilance database
por: Zhu, Jianhong, et al.
Publicado: (2021)

Immune checkpoint inhibitors
por: Kroemer, Guido, et al.
Publicado: (2021)

Pulmonary Artery Intimal Sarcoma in a Patient with Lynch Syndrome: Response to an Immune Checkpoint Inhibitor
por: Mounai, Yue, et al.
Publicado: (2023)

Identification and prediction of immune checkpoint inhibitors-related pneumonitis by machine learning
por: Gong, Li, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_t58vfp9uulkcn5coh3ug0s8ie8